Twist Bioscience Co. (NASDAQ:TWST) CEO Sells $53,472.00 in Stock

Twist Bioscience Co. (NASDAQ:TWST) CEO Emily M. Leproust sold 1,114 shares of the stock in a transaction on Tuesday, July 2nd. The stock was sold at an average price of $48.00, for a total value of $53,472.00. Following the sale, the chief executive officer now owns 504,732 shares in the company, valued at approximately $24,227,136. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Twist Bioscience Stock Performance

TWST stock traded up $0.45 on Friday, reaching $48.45. The company’s stock had a trading volume of 258,253 shares, compared to its average volume of 1,038,783. The firm has a market cap of $2.82 billion, a PE ratio of -14.41 and a beta of 1.80. The business has a fifty day simple moving average of $45.23 and a two-hundred day simple moving average of $38.71. Twist Bioscience Co. has a 12-month low of $14.42 and a 12-month high of $55.26.

Twist Bioscience (NASDAQ:TWST) last issued its quarterly earnings data on Thursday, May 2nd. The company reported ($0.79) EPS for the quarter, topping the consensus estimate of ($0.84) by $0.05. The business had revenue of $75.30 million during the quarter, compared to analyst estimates of $70.70 million. Twist Bioscience had a negative net margin of 69.24% and a negative return on equity of 31.61%. The company’s revenue for the quarter was up 25.1% on a year-over-year basis. During the same period in the prior year, the business earned ($1.06) EPS. As a group, research analysts anticipate that Twist Bioscience Co. will post -3.08 earnings per share for the current fiscal year.

Institutional Trading of Twist Bioscience

Large investors have recently bought and sold shares of the company. American International Group Inc. raised its position in shares of Twist Bioscience by 0.8% in the 1st quarter. American International Group Inc. now owns 28,506 shares of the company’s stock worth $978,000 after acquiring an additional 213 shares in the last quarter. D.A. Davidson & CO. increased its stake in Twist Bioscience by 3.4% during the 4th quarter. D.A. Davidson & CO. now owns 16,774 shares of the company’s stock valued at $618,000 after purchasing an additional 554 shares in the last quarter. EdgeRock Capital LLC purchased a new position in Twist Bioscience in the 4th quarter worth approximately $30,000. Swiss National Bank lifted its holdings in shares of Twist Bioscience by 0.8% during the first quarter. Swiss National Bank now owns 114,000 shares of the company’s stock valued at $3,911,000 after purchasing an additional 900 shares in the last quarter. Finally, ProShare Advisors LLC lifted its position in Twist Bioscience by 10.2% during the first quarter. ProShare Advisors LLC now owns 14,444 shares of the company’s stock valued at $496,000 after purchasing an additional 1,336 shares during the period.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the stock. Evercore ISI raised their price objective on shares of Twist Bioscience from $46.00 to $50.00 and gave the company an “outperform” rating in a research report on Friday, May 3rd. Guggenheim assumed coverage on Twist Bioscience in a research report on Tuesday, June 4th. They issued a “buy” rating and a $53.00 target price for the company. Barclays raised their price objective on Twist Bioscience from $45.00 to $60.00 and gave the company an “overweight” rating in a research note on Friday, June 28th. Scotiabank lifted their target price on shares of Twist Bioscience from $43.00 to $48.00 and gave the stock a “sector outperform” rating in a research note on Monday, May 6th. Finally, Robert W. Baird increased their price target on shares of Twist Bioscience from $39.00 to $40.00 and gave the company an “outperform” rating in a research report on Friday, May 3rd. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $48.50.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.